Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with

WALTHAM, Mass., Nov. 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The inducement awards were approved on November 20, 20

WALTHAM, Mass., Oct. 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that, Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 2,900,000 shares of common stock of Aeglea to two non-executive employees as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan"). The stock options were approved on October 2, 2023 and were material to each employee's

4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

3 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

4 - Spyre Therapeutics, Inc. (0001636282) (Issuer)

424B3 - Spyre Therapeutics, Inc. (0001636282) (Filer)

8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

8-K - Spyre Therapeutics, Inc. (0001636282) (Filer)

Company will begin trading on Nasdaq under trading symbol "SYRE" effective November 28, 2023 Biotechnology leader Cameron Turtle, DPhil, appointed as Chief Executive Officer and Member of the Board of Directors alongside industry veterans Jeffrey Albers and Laurie Stelzer Management team with deep IBD experience expanded to advance pipeline of product candidates designed to improve both efficacy and convenience of therapies for IBD patients, including half-life extended antibodies targeting α4β7 (SPY001) and TL1A (SPY002), which are both on track to enter clinical studies in 2024 $205 million of cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, with

AUSTIN, Texas, Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Hunter C. Smith to its board of directors. Mr. Smith currently serves as the chief financial officer of Rhythm Pharmaceuticals. "We are excited to welcome Hunter to our board of directors and to the Aeglea family," said Anthony Quinn, M.B Ch.B, Ph.D., president and chief executive officer of Aeglea. "Hunter brings a wealth of experience as a biotech leader including corporate strategy, global commercial planning and product

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights. "2021 is proving to be a pivotal year for Aeglea. In the second quarter, we achieved a significant milestone in our second clinical development program. With the initiation of dosing in our Phase 1/2 clinical trial of AGLE-177, Aeglea is making progress for patients who suffer from Homocystinuria, a rare and progressive d

AUSTIN, Texas and WALTHAM, Mass., June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of Aeglea's Board of Directors approved the grant of stock options to new employees (including the new members of management) as equity inducement awards under the Aeglea BioTherapeutics, Inc. 2018 Equity Inducement Plan. The stock options were approved on June 21, 2023 and were material to each employee's acceptance of employment with Aeglea, in accordance with Nasdaq Listing Rule 5635(c)(4). Cameron Turtle, the Chief Operating Officer of Aegl

AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study, PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), met the primary endpoint with a statistically significant reduction in plasma arginine from baseline after 24 weeks of treatment with pegzilarginase (p <0.0001). Importantly, pronounced and sustained plasma arginine reduction was accompanied by a positive trend in Gross Motor Function Measure Part E (GMFM-E), a key clinical assessment of

AUSTIN, Texas, Dec. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it will host an investor conference call and webcast tomorrow morning to discuss the topline results from the PEACE Phase 3 clinical trial of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). Investors and the public are invited to listen to a live audio webcast of the conference call on December 6, 2021, at 8:00am ET, which can be accessed prior to the start of the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (In

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)

SC 13G/A - Spyre Therapeutics, Inc. (0001636282) (Subject)